These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16779276)

  • 21. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spironolactone + ace inhibitor or sartan: risk of hyperkalaemia.
    Prescrire Int; 2004 Apr; 13(70):58. PubMed ID: 15148978
    [No Abstract]   [Full Text] [Related]  

  • 23. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study.
    Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
    BMJ; 2003 Nov; 327(7424):1141-2. PubMed ID: 14615339
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug safety in patients with heart failure.
    Juurlink DN; Hansten PD
    Arch Intern Med; 2005 Jan; 165(1):118. PubMed ID: 15642888
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical experience with spironolactone in pediatrics.
    Buck ML
    Ann Pharmacother; 2005 May; 39(5):823-8. PubMed ID: 15811903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia?
    Raebel MA; McClure DL; Chan KA; Simon SR; Feldstein AC; Lafata JE; Andrade SE; Gunter MJ; Nelson WW; Roblin D; Platt R
    Ann Pharmacother; 2007 Feb; 41(2):193-200. PubMed ID: 17284506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The positive predictive value of a hyperkalemia diagnosis in automated health care data.
    Raebel MA; Smith ML; Saylor G; Wright LA; Cheetham C; Blanchette CM; Xu S
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1204-8. PubMed ID: 20878650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The 10-minute consultation. Accidental finding: hyperkalemia. Caution with analgesics and bananas].
    Lenz T
    MMW Fortschr Med; 2005 Jan; 147(4):59-60. PubMed ID: 15745346
    [No Abstract]   [Full Text] [Related]  

  • 29. The effect of low-dose spironolactone on resistant hypertension.
    Engbaek M; Hjerrild M; Hallas J; Jacobsen IA
    J Am Soc Hypertens; 2010; 4(6):290-4. PubMed ID: 21130975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use and side-effect profile of spironolactone in a private cardiologist's practice.
    Williams EM; Katholi RE; Karambelas MR
    Clin Cardiol; 2006 Apr; 29(4):149-53. PubMed ID: 16649723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computerized surveillance of adverse drug events in hospital patients.
    Classen DC; Pestotnik SL; Evans RS; Burke JP
    JAMA; 1991 Nov; 266(20):2847-51. PubMed ID: 1942452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hyperkalemia with potassium-sparing and potassium-losing diuretics. Results from the Comprehensive Hospital Drug Monitoring Bern (CHDM)].
    Utiger F; Hoigné R; Maurer P; D'Andrea Jaeger M; Nef S; Zoppi M; Maibach R; Künzi UP
    Schweiz Med Wochenschr; 1990 Dec; 120(50):1933-6. PubMed ID: 2270447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort.
    Abbas S; Ihle P; Harder S; Schubert I
    Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):406-13. PubMed ID: 25683504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age.
    Dinsdale C; Wani M; Steward J; O'Mahony MS
    Age Ageing; 2005 Jul; 34(4):395-8. PubMed ID: 15955761
    [No Abstract]   [Full Text] [Related]  

  • 36. Spironolactone and congestive heart-failure.
    Georges B; Beguin C; Jadoul M
    Lancet; 2000 Apr; 355(9212):1369-70. PubMed ID: 10776778
    [No Abstract]   [Full Text] [Related]  

  • 37. Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease.
    Thomason JD; Rockwell JE; Fallaw TK; Calvert CA
    J Vet Cardiol; 2007 Nov; 9(2):103-8. PubMed ID: 17983885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients.
    Matsumoto Y; Kageyama S; Yakushigawa T; Arihara K; Sugiyama T; Mori Y; Sugiyama H; Ohmura H; Shio N
    Cardiology; 2009; 114(1):32-8. PubMed ID: 19342857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Normal ECG or peaked T waves?
    Hancock EW
    Hosp Pract (1995); 1998 May; 33(5):19-20. PubMed ID: 9606350
    [No Abstract]   [Full Text] [Related]  

  • 40. Adverse drug events with hyperkalaemia during inpatient stays: evaluation of an automated method for retrospective detection in hospital databases.
    Ficheur G; Chazard E; Beuscart JB; Merlin B; Luyckx M; Beuscart R
    BMC Med Inform Decis Mak; 2014 Sep; 14():83. PubMed ID: 25212108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.